SCHEMBL13870919

SCHEMBL13870919

O=C(Nc1ccccc1C(=O)O)c1cc(S(=O)(=O)N2CCCCCC2)ccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 1.00
MEN1 O00255 6/20 1.00
SMN1; SMN2 Q16637 2/20 0.76
SLC16A1 P53985 1/20 0.71
TSHR P16473 2/20 0.70
TP53 P04637 1/20 0.69
ALDH1A1 P00352 5/20 0.66
POLB P06746 2/20 0.66
LMNA P02545 3/20 0.65
KDM4E B2RXH2 3/20 0.65
GFER P55789 1/20 0.65
HTT P42858 2/20 0.65
USP2 O75604 1/20 0.62
CREBBP Q92793 1/20 0.62
MAPT P10636 1/20 0.62
HPGD P15428 1/20 0.62
NPY1R P25929 1/20 0.62
NPY2R P49146 1/20 0.62
PAX8 Q06710 1/20 0.62
RCE1 Q9Y256 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13870923 0.99 KMT2A (0.98) KMT2AMEN1SMN1; SMN2SLC16A1TSHR
SCHEMBL13870886 0.89 KMT2A (0.80) KMT2AMEN1SMN1; SMN2SLC16A1TP53
SCHEMBL17479136 0.88 SMN1; SMN2 (0.98) KMT2AMEN1SMN1; SMN2TSHRALDH1A1
SCHEMBL13870898 0.84 MEN1 (1.00) KMT2AMEN1SMN1; SMN2SLC16A1TSHR
SCHEMBL29534267 0.83 SLC16A1 (1.00) KMT2AMEN1SMN1; SMN2SLC16A1TP53
SCHEMBL31615370 0.83 SLC16A1 (1.00) KMT2AMEN1SMN1; SMN2SLC16A1TP53
SCHEMBL13870931 0.83 TP53 (0.98) KMT2AMEN1SMN1; SMN2TSHRTP53
SCHEMBL13870930 0.83 KMT2A (0.98) KMT2AMEN1SMN1; SMN2SLC16A1TP53
SCHEMBL1708867 0.83 TSHR (1.00) KMT2AMEN1SMN1; SMN2TSHRALDH1A1
SCHEMBL13870909 0.82 TP53 (1.00) KMT2AMEN1SMN1; SMN2TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use NR1H2, NR1H3, HRH2 KMT2A 2570/4885MEN1 2859/4885SMN1; SMN2 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.